Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News

Experts Push Back on WHO’s ‘Misleading’ Portrayal of ECT

Leading psychiatry groups say WHO guidance on ECT risks stigmatizing and reducing access to a safe, effective, and sometimes life-saving treatment for patients with severe mental illness.

Do Early Birds Have a Lower Risk for ALS?

Earlier bedtime and wake time and regular physical activity are associated with a significant reduction in ALS risk, a new study shows.

Halting MOGAD Treatment Tied to Lower Relapse Risk

Stopping treatment for myelin oligodendrocyte glycoprotein antibody-associated disease is linked to fewer relapses than treatment continuation, new research shows.

FDA OKs Drug to Treat Neurologic Symptoms in Hunter Syndrome

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

FDA Seeks New Warning for Certain Parkinson's Drugs

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish Lawmakers Vote Against Allowing Assisted Dying

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

Todays Updates

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

Previously treated patients with NSCLC respond to anti-CTLA-4 therapy.

Todays Updates

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

Previously treated patients with NSCLC respond to anti-CTLA-4 therapy.

Latest News

Leading psychiatry groups say WHO guidance on ECT risks stigmatizing and reducing access to a safe, effective, and sometimes life-saving treatment for patients with severe mental illness.

Earlier bedtime and wake time and regular physical activity are associated with a significant reduction in ALS risk, a new study shows.

Stopping treatment for myelin oligodendrocyte glycoprotein antibody-associated disease is linked to fewer relapses than treatment continuation, new research shows.

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

News All Time

Therapeutic Research in Alzheimer’s Disease: What Is New?

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Adults With IDDs Face ‘Mental Health Crisis’

Adults with IDDs face disproportionately higher rates of anxiety and depression and barriers to care, prompting researchers to characterize the situation as a ‘mental health crisis.’

Reframing Dyslexia: Ancient Genes, Modern Skill

Study argues to move beyond ‘reading genes’ — focus on conserved neural-development networks in humans to improve early screening and identify therapeutic leads.

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.